Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.

[1]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Tannock,et al.  Under-reporting of harm in clinical trials. , 2016, The Lancet. Oncology.

[3]  M. Krzyzanowska,et al.  Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study , 2015, PloS one.

[4]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[5]  M. Gilbert,et al.  Bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[6]  M. Gore,et al.  Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. , 2014, The Lancet. Oncology.

[7]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jianming Xu,et al.  Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) , 2014, Gastric Cancer.

[9]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[10]  F. Saad,et al.  Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[12]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Shin,et al.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[14]  M. Parmar,et al.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[15]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[16]  P. Fasching,et al.  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Philip,et al.  Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. , 2013, European journal of cancer.

[18]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[19]  M. Spielmann,et al.  Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer. , 2013, Breast cancer.

[20]  R. Greil,et al.  AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Carrato,et al.  Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Sledge,et al.  Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. , 2013, The oncologist.

[23]  K. Darwiche,et al.  Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer , 2013, OncoTargets and therapy.

[24]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[26]  K. Flaherty,et al.  Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[28]  B. Esterni,et al.  BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  G. Scagliotti,et al.  Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Santoro,et al.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Scheithauer,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  G. Scagliotti,et al.  Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[35]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Greil,et al.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Ming-Hui Chen,et al.  Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. , 2012, American heart journal.

[38]  James A Young,et al.  Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.

[39]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[40]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[41]  J. Moslehi,et al.  Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. , 2011, Circulation.

[42]  Y. Ba,et al.  Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. , 2011, Chinese journal of cancer.

[43]  M. Kudo,et al.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. , 2011, European journal of cancer.

[44]  J. Hainsworth,et al.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial , 2011, The Lancet.

[45]  D. Kerr,et al.  Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Van Cutsem,et al.  Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Chih-Hsin Yang,et al.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Michael Thomas,et al.  Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  E. Van Cutsem,et al.  Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.

[51]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[52]  D. Trafalis,et al.  Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study , 2010, Oncology.

[53]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Stockler,et al.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[57]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[58]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  G. Scagliotti,et al.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[61]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Schiller,et al.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  K. Coombes,et al.  Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. , 2010, The Journal of clinical investigation.

[64]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[65]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  N. Petrelli,et al.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  A. Hauschild,et al.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[71]  P. Bycott,et al.  Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study , 2008, The Lancet.

[72]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[73]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[74]  R. Herbst,et al.  Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[77]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[78]  D. Mukhopadhyay,et al.  Direct Evidence for Endothelial Vascular Endothelial Growth Factor Receptor-1 Function in Nitric Oxide–Mediated Angiogenesis , 2006, Circulation research.

[79]  L. Ellis,et al.  Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer , 2006, Clinical Cancer Research.

[80]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[83]  J. Deeks.  Systematic reviews of evaluations of diagnostic and screening tests , 2001, BMJ : British Medical Journal.

[84]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[85]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[86]  T. Perren,et al.  Improved Survival with Bevacizumab in Advanced Cervical Cancer. , 2017, The New England journal of medicine.

[87]  J. Thigpen.  OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer , 2012 .

[88]  J. Thigpen,et al.  A Phase 3 Trial of Bevacizumab in Ovarian Cancer , 2012 .

[89]  M. Schott.  Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial , 2012 .

[90]  A. Tsao.  Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) , 2012 .

[91]  M. Dickler,et al.  RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2012 .

[92]  E. Chiorean.  Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2012 .

[93]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[94]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[95]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .